Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies

N Dimasi; R Fleming; H Wu; C Gao

doi:10.1016/j.ymeth.2018.08.004

Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies

Methods. 2019 Feb 1:154:77-86. doi: 10.1016/j.ymeth.2018.08.004. Epub 2018 Aug 11.

Authors

N Dimasi¹, R Fleming², H Wu², C Gao³

Affiliations

¹ Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA. Electronic address: [email protected].
² Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA.
³ Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, MD, USA. Electronic address: [email protected].

PMID: 30102989
DOI: 10.1016/j.ymeth.2018.08.004

Abstract

In recent years, bispecific antibodies (BisAbs) have emerged as novel pharmaceutical candidates owing to their ability to engage two disease mediators simultaneously, thus providing a possible alternative therapeutic approach in complex diseases such as cancer and inflammation. Here we provide an overview of the molecular design, recombinant expression in mammalian cells and purification of BisAbs based on full-length IgG-scFv formats. Practical considerations and strategies to optimize transient expression and purification are also discussed.

Keywords: Affinity purification; Antibody scFv fusion; Bispecific antibodies engineering; Bispecific antibody expression; Bispecific bivalent antibodies; ScFv.

Publication types

Review

MeSH terms

Animals
Antibodies, Bispecific / genetics*
Antibodies, Bispecific / isolation & purification
Gene Expression
Humans
Immunoglobulin G / genetics*
Immunoglobulin G / isolation & purification
Protein Engineering / methods*

Substances

Antibodies, Bispecific
Immunoglobulin G